Vanguard National Trust
EDIT icon

Vanguard National Trust’s Editas Medicine EDIT Stock Holding History

Vanguard National Trust’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-156
Closed -$385 – 801
2026
Q1 		$385 Buy
+156
New +$330 ﹤0.01% 736

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard National Trust's EDIT Position: Q2 2026 in Review

Vanguard National Trust sold out of Editas Medicine (EDIT) in Q2 2026, closing a stake of 156 shares — an estimated $385 sold.

Vanguard National Trust first reported a position in EDIT in Q1 2026 and held it in 1 quarter. The position peaked at $385 in Q1 2026. 212 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Vanguard National Trust reported no remaining Editas Medicine position as of Q2 2026 after selling out during the quarter.
  • Vanguard National Trust sold 156 Editas Medicine shares in Q2 2026, an estimated $385.
  • Vanguard National Trust first reported a position in Editas Medicine in Q1 2026 and held it in 1 quarter.
  • Vanguard National Trust's Editas Medicine position peaked at $385 in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Vanguard National Trust's 13F filing for Q2 2026, filed 13 Aug 2026.